ALKERMES | ALKS - Stock


ALKERMES reported $336.7M in Stock for its fiscal quarter ending in March of 2026.





Stock Change Date
AbbVie USD 5.05B 98M Mar/2026
Acadia Pharmaceuticals USD 31.57M 3.1M Mar/2026
ALKERMES USD 336.7M 140.08M Mar/2026
Amgen USD 6.19B 39M Mar/2026
Biogen USD 1.95B 219.1M Mar/2026
BioMarin Pharmaceutical USD 1.27B 25.66M Mar/2026
Bristol-Myers Squibb USD 2.76B 66M Mar/2026
Coherus Biosciences USD 3.17M 1.12M Dec/2025
Eli Lilly USD 14.53B 785M Mar/2026
Gilead Sciences USD 1.91B 140M Mar/2026
Heron Therapeutics USD 54.57M 2.33M Dec/2022
Ionis Pharmaceuticals USD 5.56M 4.49M Mar/2026
J&J USD 14.58B 392M Mar/2026
Merck USD 6.48B 179M Mar/2026
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Neurocrine Biosciences USD 64.5M 4.5M Mar/2026
Otsuka Holdings JPY 374.32B 23.79B Dec/2025
Pfizer USD 10.67B 13M Mar/2026
Regeneron Pharmaceuticals USD 3.1B 97.2M Mar/2026
Vertex Pharmaceuticals USD 1.77B 79.9M Mar/2026